Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Research

Prognostic significance of HLA-G in patients with colorectal cancer: a meta-analysis and bioinformatics analysis

Authors: Yingying Zhang, Siying He, Lisha Yu, Chao Shi, Yanyue Zhang, Shiyue Tang

Published in: BMC Cancer | Issue 1/2023

Abstract

Purpose

Human leukocyte antigen-G (HLA-G) has been reported to be aberrantly expressed in colorectal cancer (CRC); however, its prognostic value remains controversial. Hence, our meta-analysis aims to assess the prognostic value of HLA-G in CRC patients based on published literature and The Cancer Genome Atlas (TCGA) datasets.

Methods

A systematic search was conducted on relevant studies retrieved from four electronic databases including PubMed, Embase, Web of Science and Cochrane Library. Hazard ratios (HRs) with 95% confidence intervals (CIs) were recorded to be applied as effective values. Fixed-effects models or random-effects models were applied on the basis of the value of heterogeneity (I ²). Publication bias was analyzed by Begg’s and Egger’s tests. In addition, the results were validated by using TCGA datasets.

Results

Thirteen studies comprising 3896 patients were incorporated into this meta-analysis. The pooled results showed that HLA-G expression was significantly associated with poor overall survival (OS) in both the univariate analysis (HR = 1.44, 95% CI: 1.14–1.83, P = 0.002) and the multivariate analysis (HR = 1.55, 95% CI: 1.23–1.95, P < 0.001). Nevertheless, the expression of HLA-G is not related to age, sex, tumor type, tumor differentiation, TNM stage, or distant metastasis but lymph node metastasis. Notably, the prognosis of colorectal cancer was not consistent with the analysis result from TCGA data.

Conclusion

HLA-G expression was significantly related to poor OS in CRC according to the results of our meta-analysis. However, we found that the prognostic significance was inconsistent with our results according to the TCGA data in CRC. Hence, more research is still needed to further illustrate the prognostic role of HLA-G in CRC.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64. https://doi.org/10.3322/caac.21601.CrossRefPubMed

Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837–49. https://doi.org/10.7150/ijbs.64077.CrossRefPubMedPubMedCentral

Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Immunotherapy, inflammation and colorectal cancer. Cells. 2020;9(3): 618. https://doi.org/10.3390/cells9030618.CrossRefPubMedPubMedCentral

Guraya SY. Pattern, stage, and time of recurrent colorectal cancer after curative surgery. Clin Colorectal Cancer. 2019;18(2):e223–8. https://doi.org/10.1016/j.clcc.2019.01.003.CrossRefPubMed

Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci U S A. 1987;84(24):9145–9. https://doi.org/10.1073/pnas.84.24.9145.CrossRefPubMedPubMedCentral

Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990;248(4952):220–3. https://doi.org/10.1126/science.2326636.CrossRefPubMed

Xu X, Zhou Y, Wei H. Roles of HLA-G in the maternal-fetal immune microenvironment. Front Immunol. 2020;11: 592010. https://doi.org/10.3389/fimmu.2020.592010.CrossRefPubMedPubMedCentral

Zhuang B, Shang J, Yao Y. HLA-G: an important mediator of maternal-fetal immune-tolerance. Front Immunol. 2021;12:744324. https://doi.org/10.3389/fimmu.2021.744324.CrossRefPubMedPubMedCentral

10.

Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J. HLA-G: an immune checkpoint molecule. Adv Immunol. 2015;127:33–144. https://doi.org/10.1016/bs.ai.2015.04.001.CrossRefPubMed

11.

Morandi F, Pistoia V. Interactions between HLA-G and HLA-E in physiological and pathological conditions. Front Immunol. 2014;5:5. https://doi.org/10.3389/fimmu.2014.00394.CrossRef

12.

Krijgsman D, Roelands J, Hendrickx W, Bedognetti D, Kuppen PJK. HLA-G: a new immune checkpoint in cancer? Int J Mol Sci. 2020;21(12):4528. https://doi.org/10.3390/ijms21124528.CrossRefPubMedPubMedCentral

13.

Attia JVD, Dessens CE, van de Water R, Houvast RD, Kuppen PJK, Krijgsman D, Attia JVD, Dessens CE, van de Water R, Houvast RD, Kuppen PJK, Krijgsman D. The Molecular and functional characteristics of HLA-G and the Interaction with its receptors: where to intervene for cancer immunotherapy? Int J Mol Sci. 2020;21(22): 8678. https://doi.org/10.3390/ijms21228678.CrossRefPubMedPubMedCentral

14.

Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 1998;95(8):4510–5. https://doi.org/10.1073/pnas.95.8.4510.CrossRefPubMedPubMedCentral

15.

Xu HH, Gan J, Xu DP, Li L, Yan WH. Comprehensive transcriptomic analysis reveals the role of the Immune checkpoint HLA-G molecule in cancers. Front Immunol. 2021;12: 614773. https://doi.org/10.3389/fimmu.2021.614773.CrossRefPubMedPubMedCentral

16.

Lin A, Yan WH. Intercellular transfer of HLA-G: its potential in cancer immunology. Clin Transl Immunology. 2019;8(9):e1077. https://doi.org/10.1002/cti2.1077.CrossRefPubMedPubMedCentral

17.

Yan WH. Human leukocyte antigen-G in cancer: are they clinically relevant? Cancer Lett. 2011;311(2):123–30. https://doi.org/10.1016/j.canlet.2011.07.019.CrossRefPubMed

18.

Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20(3):375–83. https://doi.org/10.1038/modpathol.3800751.CrossRefPubMed

19.

Reimers MS, Engels CC, Putter H, Morreau H, Liefers GJ, van de Velde CJ, Reimers MS, Engels CC, Putter H, Morreau H, Liefers GJ, van de Velde CJH, Kuppen PJK. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. BMC Cancer. 2014;14(1): 486. https://doi.org/10.1186/1471-2407-14-486.CrossRefPubMedPubMedCentral

20.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71.CrossRefPubMedPubMedCentral

21.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

22.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715.CrossRefPubMedPubMedCentral

23.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587-d592. https://doi.org/10.1093/nar/gkac963.CrossRefPubMed

24.

Zeestraten EC, Reimers MS, Saadatmand S, Goossens-Beumer IJ, Dekker JW, Liefers GJ, et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer. 2014;110(2):459–68. https://doi.org/10.1038/bjc.2013.696.CrossRefPubMed

25.

Guo ZY, Lv YG, Wang L, Shi SJ, Yang F, Zheng GX, Guo Z-Y, Lv Y-G, Wang L, Shi S-J, Yang F, Zheng G-X, Wen W-H, Yang A-G. Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. Cell Immunol. 2015;293(1):10–6. https://doi.org/10.1016/j.cellimm.2014.10.003.CrossRefPubMed

26.

Kirana C, Ruszkiewicz A, Stubbs RS, Hardingham JE, Hewett PJ, Maddern GJ, et al. Soluble HLA-G is a differential prognostic marker in sequential colorectal cancer disease stages. Int J Cancer. 2017;140(11):2577–86. https://doi.org/10.1002/ijc.30667.CrossRefPubMed

27.

Li JB, Ruan YY, Hu B, Dong SS, Bi TN, Lin A, Li J-B, Ruan Y-Y, Hu B, Dong S-S, Bi T-N, Lin A, Yan W-H. Importance of the plasma soluble HLA-G levels for prognostic stratification with traditional prognosticators in colorectal cancer. Oncotarget. 2017;8(30):48854–62. https://doi.org/10.18632/oncotarget.16457.CrossRefPubMedPubMedCentral

28.

Zhang RL, Zhang X, Dong SS, Hu B, Han QY, Zhang JG, Zhang R-L, Zhang X, Dong S-S, Hu B, Han Q-Y, Zhang J-G, Zhou W-J, Lin A, Yan W-H. Predictive value of different proportion of lesion HLA-G expression in colorectal cancer. Oncotarget. 2017;8(64):107441–51. https://doi.org/10.18632/oncotarget.22487.CrossRefPubMedPubMedCentral

29.

Samadi R, Mojarad EN, Molaei M, Kazerouni F, Aghdaei HA, Navidinia M, et al. Clinical value of Human Leucocyte Antigen G (HLA-G) expression in the prognosis of Colorectal Cancer. Int J Cancer Manage. 2017;10(4). https://doi.org/10.5812/ijcm.9346.

30.

Lin A, Zhang X, Zhang RL, Zhang JG, Zhou WJ, Yan WH. Clinical significance of potential unidentified HLA-G isoforms without α1 domain but containing Intron 4 in colorectal cancer patients. Front Oncol. 2018;8: 361. https://doi.org/10.3389/fonc.2018.00361.CrossRefPubMedPubMedCentral

31.

Jiao F, Zhou J, Sun H, Song X, Song Y. Plasma soluble human leukocyte antigen G predicts the long-term prognosis in patients with colorectal cancer. Transl Cancer Res. 2020;9(6):4011–9. https://doi.org/10.21037/tcr-20-2211.CrossRefPubMedPubMedCentral

32.

Chen QY, Chen YX, Han QY, Zhang JG, Zhou WJ, Zhang X, Chen Q-Y, Chen Y-X, Han Q-Y, Zhang J-G, Zhou W-J, Zhang X, Ye Y-H, Yan W-H, Lin A. Prognostic significance of Immune checkpoints HLA-G/ILT-2/4 and PD-L1 in colorectal cancer. Front Immunol. 2021;12: 679090. https://doi.org/10.3389/fimmu.2021.679090.CrossRefPubMedPubMedCentral

33.

Bennedsen ALB, Cai L, Hasselager RP, Özcan AA, Mohamed KB, Eriksen JO, Bennedsen ALB, Cai L, Hasselager RP, Özcan AA, Mohamed KB, Eriksen JO, Eiholm S, Bzorek M, Fiehn A-M, Hviid TVF, Gögenur I. An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer. BMC Cancer. 2022;22(1):62. https://doi.org/10.1186/s12885-022-09169-0.CrossRefPubMedPubMedCentral

34.

Emirzeoglu L, Olmez O, Mustafayev FNA, Berber U, Yilmaz I, Celik S, et al. Prognostic value of expression levels of miR-148a, miR-152 and HLA-G in colon cancer. Oncol Lett. 2022;24(1):226. https://doi.org/10.3892/ol.2022.13347.CrossRefPubMedPubMedCentral

35.

Wang H. MicroRNAs and apoptosis in colorectal cancer. Int J Mol Sci. 2020;21(15): 5353. https://doi.org/10.3390/ijms21155353.CrossRefPubMedPubMedCentral

36.

Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F. Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy. Front Immunol. 2021;12:808964. https://doi.org/10.3389/fimmu.2021.808964.CrossRefPubMed

37.

Shan J, Han D, Shen C, Lei Q, Zhang Y. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol. 2022;13: 1016646. https://doi.org/10.3389/fimmu.2022.1016646.CrossRefPubMedPubMedCentral

38.

Zhou C, Cheng X, Tu S. Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. Cancer Lett. 2021;521:119–29. https://doi.org/10.1016/j.canlet.2021.07.023.CrossRefPubMed

39.

Lin A, Yan WH. Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med. 2015;21(1):782–91. https://doi.org/10.2119/molmed.2015.00083.CrossRefPubMedPubMedCentral

40.

Peng Y, Xiao J, Li W, Li S, Xie B, He J, Peng Y, Xiao J, Li W, Li S, Xie B, He J, Liu C. Prognostic and clinicopathological value of human leukocyte antigen G in gastrointestinal cancers: a meta-analysis. Front Oncol. 2021;11: 642902. https://doi.org/10.3389/fonc.2021.642902.CrossRefPubMedPubMedCentral

41.

Bartolome J, Molto C, Benitez-Fuentes JD, Fernandez-Hinojal G, Manzano A, Perez-Segura P, Bartolome J, Molto C, Benitez-Fuentes JD, Fernandez-Hinojal G, Manzano A, Perez-Segura P, Mittal A, Tamimi F, Amir E, Ocana A. Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis. Front Immunol. 2023;14: 1165813. https://doi.org/10.3389/fimmu.2023.1165813.CrossRefPubMedPubMedCentral

42.

Lin A, Zhu CC, Chen HX, Chen BF, Zhang X, Zhang JG, et al. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell Lung cancer. J Cell Mol Med. 2010;14(9):2318–29. https://doi.org/10.1111/j.1582-4934.2009.00858.x.CrossRefPubMed

43.

Yan WH, Liu D, Lu HY, Li YY, Zhang X, Lin A. Significance of tumour cell HLA-G5/-G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients. J Cell Mol Med. 2015;19(4):778–85. https://doi.org/10.1111/jcmm.12400.CrossRefPubMedPubMedCentral

44.

Tronik-Le Roux D, Renard J, Verine J, Renault V, Tubacher E, LeMaoult J, et al. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients. Mol Oncol. 2017;11(11):1561–78. https://doi.org/10.1002/1878-0261.12119.CrossRefPubMedPubMedCentral

45.

Arnaiz-Villena A, Juarez I, Suarez-Trujillo F, López-Nares A, Vaquero C, Palacio-Gruber J, et al. HLA-G: function, polymorphisms and pathology. Int J Immunogenet. 2021;48(2):172–92. https://doi.org/10.1111/iji.12513.CrossRefPubMed

46.

Gan J, Di XH, Yan ZY, Gao YF, Xu HH. HLA-G 3’UTR polymorphism diplotypes and soluble HLA-G plasma levels impact Cervical cancer susceptibility and prognosis. Front Immunol. 2022;13: 1076040. https://doi.org/10.3389/fimmu.2022.1076040.CrossRefPubMedPubMedCentral

47.

Rokhafrooz S, Ghadiri A, Ghandil P, Ghafourian M, Hossaini SH, Daraei N, et al. Association between HLA-G 14 bp gene polymorphism and serum sHLA-G protein concentrations in preeclamptic patients and normal pregnant women. Immunol Invest. 2018;47(6):558–68. https://doi.org/10.1080/08820139.2018.1467925.CrossRefPubMed

48.

Martelli-Palomino G, Pancotto JA, Muniz YC, Mendes-Junior CT, Castelli EC, Massaro JD, Martelli-Palomino G, Pancotto JA, Muniz YC, Mendes-Junior CT, Castelli EC, Massaro JD, Krawice-Radanne I, Poras I, Rebmann V, Carosella ED, Rouas-Freiss N, Moreau P, Donadi EA. Polymorphic sites at the 3’ untranslated region of the HLA-G gene are associated with differential hla-g soluble levels in the Brazilian and French population. PLoS One. 2013;8(10): e71742. https://doi.org/10.1371/journal.pone.0071742.CrossRefPubMedPubMedCentral

49.

Mori A, Nishi H, Sasaki T, Nagamitsu Y, Kawaguchi R, Okamoto A, Mori A, Nishi H, Sasaki T, Nagamitsu Y, Kawaguchi R, Okamoto A, Kuroda M, Isaka K. HLA-G expression is regulated by miR-365 in trophoblasts under hypoxic conditions. Placenta. 2016;45:37–41. https://doi.org/10.1016/j.placenta.2016.07.004.CrossRefPubMed

50.

Wang Y, Jiang X, Zhang D, Zhao Y, Han X, Zhu L, Wang Y, Jiang X, Zhang D, Zhao Y, Han X, Zhu L, Ren J, Liu Y, You J, Wang H, Cai H. LncRNA DUXAP8 as a prognostic biomarker for various cancers: a meta-analysis and bioinformatics analysis. Front Genet. 2022;13: 907774. https://doi.org/10.3389/fgene.2022.907774.CrossRefPubMedPubMedCentral

51.

Wang Y, Fu L, Lu T, Zhang G, Zhang J, Zhao Y, Wang Y, Fu L, Lu T, Zhang G, Zhang J, Zhao Y, Jin H, Yang K, Cai H. Clinicopathological and prognostic significance of long non-coding RNA MIAT in human cancers: a review and Meta-analysis. Front Genet. 2021;12: 729768. https://doi.org/10.3389/fgene.2021.729768.CrossRefPubMedPubMedCentral

52.

Li TF, Liu J, Fu SJ. The interaction of long non-coding RNA MIAT and miR-133 play a role in the proliferation and Metastasis of pancreatic carcinoma. Biomed Pharmacother. 2018;104:145–50. https://doi.org/10.1016/j.biopha.2018.05.043.CrossRefPubMed

53.

Seliger B. Role of microRNAs on HLA-G expression in human tumors. Hum Immunol. 2016;77(9):760–3. https://doi.org/10.1016/j.humimm.2016.04.006.CrossRefPubMed

54.

Zhang D, An X, Li Z, Zhang S. Role of gene promoter methylation regulated by TETs and DNMTs in the overexpression of HLA-G in MCF-7 cells. Exp Ther Med. 2019;17(6):4709–14. https://doi.org/10.3892/etm.2019.7481.CrossRefPubMedPubMedCentral

55.

Bucova M, Kluckova K, Kozak J, Rychly B, Suchankova M, Svajdler M, et al. HLA-G 14 bp Ins/Del polymorphism, plasma level of soluble HLA-G, and association with IL-6/IL-10 ratio and survival of glioma patients. Diagnostics (Basel). 2022;12(5):1099. https://doi.org/10.3390/diagnostics12051099.CrossRefPubMed

56.

Whiteside TL. Tumor-infiltrating lymphocytes and their role in solid tumor progression. Exp Suppl. 2022;113:89–106. https://doi.org/10.1007/978-3-030-91311-3_3.CrossRefPubMedPubMedCentral

57.

Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K, Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K, Huang Q, Shi X, Ni Z, Ding N, Zhao K-N, Chang W, Wang J, Lin F, Xue X. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol. 2019;10: 2368. https://doi.org/10.3389/fimmu.2019.02368.CrossRefPubMedPubMedCentral

58.

Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol. 2000;48(1):17–26. https://doi.org/10.1016/s0165-0378(00)00070-x.CrossRefPubMed

59.

Köstlin N, Ostermeir AL, Spring B, Schwarz J, Marmé A, Walter CB, et al. HLA-G promotes myeloid-derived suppressor cell accumulation and suppressive activity during human pregnancy through engagement of the receptor ILT4. Eur J Immunol. 2017;47(2):374–84. https://doi.org/10.1002/eji.201646564.CrossRefPubMed

60.

Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in Tumor Escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood. 2011;117(26):7021–31. https://doi.org/10.1182/blood-2010-07-294389.CrossRefPubMed

61.

Sieminska I, Baran J. Myeloid-derived suppressor cells in colorectal cancer. Front Immunol. 2020;11:11. https://doi.org/10.3389/fimmu.2020.01526.CrossRef

62.

Zheng G, Jia L, Yang A-G. Roles of HLA-G/KIR2DL4 in breast cancer immune microenvironment. Front Immunol. 2022;13:13. https://doi.org/10.3389/fimmu.2022.791975.CrossRef

63.

Morandi F, Airoldi I. HLA-G and other immune checkpoint molecules as targets for novel combined immunotherapies. Int J Mol Sci. 2022;23(6):2925. https://doi.org/10.3390/ijms23062925.CrossRefPubMedPubMedCentral

64.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of Immunotherapy in Urologic Cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267–79. https://doi.org/10.1016/j.eururo.2015.02.032.CrossRefPubMed

65.

Gilead buys into Tizona's anti-HLA-G strategy. Cancer Discov. 2020;10(10):1433. https://doi.org/10.1158/2159-8290.CD-NB2020-077.

Title: Prognostic significance of HLA-G in patients with colorectal cancer: a meta-analysis and bioinformatics analysis
Authors: Yingying Zhang
Siying He
Lisha Yu
Chao Shi
Yanyue Zhang
Shiyue Tang
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11522-w

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity

Clinical research of the value of high-risk CTV setting on intensity-modulated radiotherapy for stage IIB-IVA cervical cancer

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing

Trends in overall mortality among US veterans with primary myelofibrosis

Construction and verification of a novel circadian clock related long non-coding RNA model and prediction of treatment for survival prognosis in patients with hepatocellular carcinoma